NOVABAY PHARMACEUTICALS INC (NBY) Forecast, Price Target & Analyst Ratings
NYSEARCA:NBY • US66987P4090
1.23 USD
-0.03 (-2.38%)
Last: Mar 11, 2026, 02:38 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NOVABAY PHARMACEUTICALS INC (NBY).
Forecast Snapshot
Consensus Price Target
N/A
N/A
Next Earnings Forecast
Release DateMar 31, 2026
PeriodQ1 / 2025
EPS Estimate-$0.24
Revenue Estimate3.03M
ChartMill Buy Consensus
80.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $1.23 to mean target of N/A, Based on 5 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
80.00%
NBY was analyzed by 5 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about NBY.
In the previous month the buy percentage consensus was at a similar level.
Only 5 analysts analyzed NBY. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-11-11 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2023-08-11 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2022-05-20 | Ascendiant Capital | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 31, 2026
PeriodQ1 / 2025
EPS Estimate-$0.24
Revenue Estimate3.03M
Revenue Q2Q15.17%
EPS Q2Q95.38%
Number of Analysts2
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
NBY is expected to report earnings on 3/31/2026. The consensus EPS estimate for the next earnings is -0.24 USD and the consensus revenue estimate is 3.03M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 14.4M 71.02% | 14.726M 2.26% | 9.781M -33.58% | 12.12M 23.91% | 16.004M 32.05% | |
| EBITDA YoY % growth | -7.2M -6.82% | -4.8M 33.33% | -4.934M -2.79% | -2.626M 46.78% | N/A | |
| EBIT YoY % growth | -7.68M -11.95% | -5.003M 34.86% | -4.974M 0.58% | -4.04M 18.78% | -2.586M 36.00% | |
| Operating Margin | -53.33% | -33.97% | -50.85% | -33.33% | -16.16% | |
| EPS YoY % growth | -260.05 -41.52% | -111.65 57.07% | N/A 98.72% | -0.87 39.01% | -0.38 55.81% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.24 95.38% | -0.21 84.52% | -0.21 35.73% | -0.20 -81.82% | -0.20 16.67% | -0.11 47.62% | -0.12 42.86% | 0.03 115.00% |
| Revenue Q2Q % growth | 3.03M 15.17% | 3.03M 26.25% | 3.03M 24.13% | 3.03M 31.23% | 3.636M 20.00% | 3.317M 9.47% | 3.796M 25.28% | 5.256M 73.47% |
| EBITDA Q2Q % growth | -808K 48.17% | -606K 41.17% | -606K 41.11% | -606K 51.48% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -1.111M 29.28% | -1.01M 4.08% | -1.01M 4.81% | -1.01M 21.64% | -1.232M -10.91% | -727.2K 28.00% | -838.3K 17.00% | 212.1K 121.00% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
NOVABAY PHARMACEUTICALS INC / NBY Forecast FAQ
Can you provide the upcoming earnings date for NOVABAY PHARMACEUTICALS INC?
NOVABAY PHARMACEUTICALS INC (NBY) will report earnings on 2026-03-31, after the market close.
Can you provide the consensus estimates for NOVABAY PHARMACEUTICALS INC next earnings?
The consensus EPS estimate for the next earnings of NOVABAY PHARMACEUTICALS INC (NBY) is -0.24 USD and the consensus revenue estimate is 3.03M USD.
What is the consensus rating for NOVABAY PHARMACEUTICALS INC (NBY) stock?
The consensus rating for NOVABAY PHARMACEUTICALS INC (NBY) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.